Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Compugen Ltd. (NASDAQ: CGEN), a leader in cancer immunotherapy and advanced computational drug target discovery, announced that it will unveil its financial results for the fourth quarter and full year of 2025 on March 2, 2026, prior to the opening of U.S. financial markets. To discuss these results and provide insights into the company's current operations and future direction, Compugen's management will host a conference call and webcast at 8:30 AM ET on the same day. Interested parties can access the live conference by dialing a U.S. toll-free number or an international number, with the option for a replay available on Compugen's website afterwards.

Compugen utilizes its proprietary AI/ML-powered discovery platform, Unigen™, to identify novel drug targets and develop innovative cancer immunotherapies. The company is actively advancing several promising programs, particularly those targeting the TIGIT pathway. It is currently developing COM902, a high-affinity anti-TIGIT antibody in Phase 1 trials, alongside a bispecific antibody rilvegostomig in Phase 3 development, in collaboration with AstraZeneca. Notably, the TIGIT element of rilvegostomig is linked to the insights gained from COM902.

Additionally, Compugen's pipeline includes COM701, a potential first-in-class anti-PVRIG antibody, and GS-0321 (previously COM503), an anti-IL-18 binding protein antibody, both in early development stages. The company is committed to explore new mechanisms that enhance immune activation against cancer through its research initiatives in immuno-oncology.

For any investor inquiries, Compugen has provided contact information for their investor relations team via email and phone. The company's shares are publicly traded under the ticker symbol CGEN on both Nasdaq and the Tel Aviv Stock Exchange.

As Compugen Ltd. (NASDAQ: CGEN) approaches the release of its fourth quarter and full-year 2025 results on March 2, 2026, investors should prepare for a key moment in the company’s trajectory. This presentation comes at a crucial time as Compugen continues to develop its innovative immunotherapy programs, largely guided by its AI/ML-powered computational platform, Unigen™.

Market sentiment surrounding biotech firms can be unpredictable, especially for clinical-stage companies like Compugen. Investors should closely analyze the tone and content of the earnings call, particularly any updates regarding their pipeline, including the Phase 1 COM902 and the Phase 3 rilvegostomig, a bispecific antibody licensed to AstraZeneca. The success and progress of these candidates are critical not only to the company's valuation but also to future funding opportunities.

Expectations may be high for Compugen, given the competitive landscape of cancer immunotherapies. If management presents favorable data or advancements in their clinical trials, it could lead to a bullish reaction in the stock price. However, caution is warranted, as any delays, disappointing results, or subdued guidance could trigger significant volatility.

Investors should also pay attention to the company's financial health, including cash reserves and burn rate, to assess sustainability through ongoing trials. Analysts will be keenly interested in forward-looking statements, especially regarding structural or regulatory shifts that may affect their operations.

In summary, while Compugen's innovative approach and clinical pipeline offer potential upside, investors should stay alert for nuances in the forthcoming results and management's commentary. Close monitoring of the stock price in the days leading up to and after the announcement will be essential for making informed investment decisions.